In a recent meta-analysis, which incorporated SOUL and FLOW research studies, injectable and oral long-acting GLP-1 RA were shown to reduce the incidence of MACE and all the subcomponents by a broadly similar amount as well as that of all-cause mortality, heart failure hospitalization, and kidney events [14]. The gene discussed is GLP1R; the disease is heart failure.